If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor Atrial Fibrillation advisory service, Decision Resources is offering an exclusive analyst call entitled Atrial Fibrillation: Will Emerging Agents With Novel Mechanisms of Action Overcome the Limitations of Current Treatments? Because this analyst call will feature major findings, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. A defining unmet medical need in atrial fibrillation is the availability of safer and more effective antiarrhythmic drugs. Current therapies are limited by unsatisfactory levels of efficacy and serious safety liabilities. Sanofi’s Multaq (dronedarone), the most recent addition to the antiarrhythmic drug armamentarium, has encountered only modest uptake since its launch and has suffered a series of setbacks. For example, in July 2011, the European Medicines Agency and the U.S. Food and Drug Administration (FDA) initiated thorough reviews of Multaq’s cardiac safety profile after its PALLAS trial was halted due to significantly increased rates of cardiovascular events in Multaq-treated patients. In the wake of this recent market event, Decision Resources has conducted a thorough review of novel antiarrhythmic drug treatments for atrial fibrillation that are in the pipeline. Several emerging therapies with new mechanisms of action are in development but it remains to be seen if these agents can overcome the limitations of current treatments. Decision Resources recently interviewed a series of thought leaders to determine what the prospects are for emerging antiarrhythmic drugs and to identify important barriers to entry in this potentially lucrative market. This 15-minute analyst call, presented by Decision Resources Analyst Matthew Killeen, Ph.D., will answer the following questions:
Dr. Killeen will conduct a live Q & A session after the presentation. Atrial Fibrillation: Will Emerging Agents With Novel Mechanisms of Action Overcome the Limitations of Current Treatments? August 16, 2011 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below.
In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Matthew Killeen, Ph.D., is an analyst on the cardiovascular and metabolic disorders team at Decision Resources, where he focuses on commercial developments in the drug markets for atrial fibrillation and venous thromboembolism. Dr. Killeen is an expert on drug safety and has authored a book on drug-induced cardiac toxicity and co-chaired a cardiac safety meeting at the FDA. He is also the author of 19 peer-reviewed journal articles on topics including atrial fibrillation, drug safety, and ventricular arrhythmias. Prior to joining the company, Dr. Killeen worked in life sciences business development for the London Technology Network and in neuroscience drug discovery at Eli Lilly. Dr. Killeen holds a Ph.D. in Cardiac Electrophysiology from Cambridge University and a B.Sc. (first class) in Pharmacology from the University of Leeds. Additionally, he has held research fellowships at Harvard Medical School and the Massachusetts General Hospital, where he studied the genetic basis of sudden cardiac death.